title: Effect on glycemic control of the addition of 2.5 mg glipizide GITS to metformin in patients with T2DM.
abstract: OBJECTIVE
  This study evaluated the effects on glycemic control of the addition of 2.5 mg glipizide GITS to metformin in patients with mild-to-moderate, but suboptimally controlled type 2 diabetes.
  
  
  METHODS
  In this multicenter, double-blind, placebo-controlled study, 122 patients with type 2 diabetes inadequately controlled (A1c 7-8.5%) on metformin (> or =1000 mg/day for > or =3 months) were randomized to 16 weeks treatment with 2.5 mg/day glipizide GITS (n=61) or placebo (n=61), in addition to their current metformin dose. The primary efficacy variable was the change in A1c from baseline to endpoint. Changes in fasting plasma glucose (FPG), insulin concentrations, lipid profile and safety variables were also measured.
  
  
  RESULTS
  The addition of glipizide GITS to metformin gave significantly greater improvements in mean A1c and FPG from baseline to endpoint than placebo addition (p<0.0002). Significantly more patients in the glipizide GITS group than in the placebo group achieved the target A1c level of A1c<7.0% (p<0.0001) and an A1c<6.5% (p<0.0033). Fasting insulin concentrations were similar in both groups and unchanged by treatment. Addition of glipizide GITS to metformin did not produce any significant or clinically relevant weight gain or changes in BMI. Both treatment regimens were well tolerated.
  
  
  CONCLUSIONS
  This study showed that the addition of 2.5 mg glipizide GITS to metformin significantly improved glucose control in patients with type 2 diabetes inadequately controlled by metformin monotherapy.
authors.affiliation: Duke University Medical Center, Division of Endocrinology, Box 3921, Durham, NC 27710, USA. feing002@mc.duke.edu
authors.forename: M
authors.initials: M
authors.lastname: Feinglos
authors.forename: G
authors.initials: G
authors.lastname: Dailey
authors.forename: W
authors.initials: W
authors.lastname: Cefalu
authors.forename: K
authors.initials: K
authors.lastname: Osei
authors.forename: J
authors.initials: J
authors.lastname: Tayek
authors.forename: W
authors.initials: W
authors.lastname: Canovatchel
authors.forename: R
authors.initials: R
authors.lastname: Chaiken
authors.forename: I
authors.initials: I
authors.lastname: Kourides
mesh_terms: D001786:Blood Glucose / Q000187:drug effects* / Q000502:physiology; D002626:Chemistry, Pharmaceutical; D003692:Delayed-Action Preparations / Q000008:administration & dosage; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005215:Fasting / Q000097:blood; D005260:Female; D005913:Glipizide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006442:Glycated Hemoglobin / Q000737:chemistry; D006801:Humans; D007003:Hypoglycemia / Q000453:epidemiology; D007328:Insulin / Q000097:blood; D008297:Male; D008687:Metformin / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged
chemical_list: D001786:Blood Glucose; D003692:Delayed-Action Preparations; D005913:Glipizide; D006442:Glycated Hemoglobin; D007328:Insulin; D008687:Metformin